TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07900438: A Study of Kidney and Cardiovascular Endpoints in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China

Sponsor: Novo Nordisk A/S · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 300 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,338,560

Rescue Site Savings

+$3,532,480

Unlock Full NCT07900438 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07900438 Rescue Dossier →